Stocks analysis

ABBV vs AES Stock Comparison

Scores Breakdown

Metric ABBV AES
📈 Growth 26/30 12/30
💰 Profitability 18/20 10/20
🏦 Financial Health 6/20 12/20
💵 Valuation 12/20 8/20
⚠️ Risk (lower is better) 8/10 4/10
Overall Score 64/100 48/100

Side-by-Side Summaries

ABBV Analysis AES Analysis

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

  • Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
  • Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.

📈 Growth & Financial Trajectory

Over the observed 7 quarters, AES's revenues hovered near $3.0B, ending around $2.42B in 2026 Q2, while net income remained positive overall, indicating resilience despite quarterly volatility. The trend shows modest growth from early 2025 into late 2025, with some weakness in 2026 Q2 driven by lower topline and mix. Overall, earnings resilience persisted through the period.

💰 Margins & Cash Flow

Gross margin ranged roughly in the high 20s and low 30s percentage; operating margin varied around the mid-teens in stronger quarters and contracted when costs rose. Net cash from operating activities was typically solid (around $1.0B per quarter), but investing cash flow was consistently negative, leading to fluctuating free cash flow and reliance on financing for liquidity.

🛡️ Balance Sheet & Liquidity

Total assets near $50B+, liabilities around $40B, and equity near $9–9.8B. Current ratio hovered below 1 in some quarters, reflecting funded working capital needs. Redeemable interests and temporary equity add complexity; overall balance sheet appears leveraged but with steady cash generation.

⚠️ Key Drivers & Risks

  • Drivers: Regulated utility earnings, renewable integration, stable demand
  • Risks: Commodity/energy price sensitivity, regulatory/policy shifts, interest-rate exposure